Aleniglipron (development code GSBR-1290) is a

small-molecule In molecular biology and pharmacology, a small molecule or micromolecule is a low molecular weight (≤ 1000 daltons) organic compound that may regulate a biological process, with a size on the order of 1 nm. Many drugs are small molecules; t ...

GLP-1 agonist Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 analogs, GLP-1RAs, or incretin mimetics, are a class of anorectic drugs that reduce blood sugar and energy intake by activating the GLP-1 receptor. They mimic the actions of ...

developed by Structure Therapeutics. It is delivered orally and is in a Phase II trial as of 2023. In June 2024, Structure Therapeutics reported positive topline data from a Phase 2a obesity study in which GSBR-1290 demonstrated clinically meaningful and statistically significant placebo-adjusted mean weight loss and generally favorable safety and tolerability results.

References

{{reflist GLP-1 receptor agonists Experimental diabetes drugs Organophosphine oxides Anilines Imidazoles Oxadiazoles Pyrazolopyridines Indoles 4-Fluorophenyl compounds Ureas Carboxamides Cyclopropanes Tetrahydropyrans